Jasper Therapeutics (NASDAQ:JSPR) Given Market Outperform Rating at JMP Securities

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report)'s stock had its "market outperform" rating reaffirmed by stock analysts at JMP Securities in a research note issued to investors on Monday,Benzinga reports. They presently have a $70.00 price objective on the stock. JMP Securities' target price would suggest a potential upside of 235.41% from the stock's previous close.

Other analysts also recently issued research reports about the company. Cantor Fitzgerald restated an "overweight" rating on shares of Jasper Therapeutics in a research note on Monday, September 9th. BMO Capital Markets assumed coverage on Jasper Therapeutics in a research report on Friday, December 6th. They issued an "outperform" rating and a $63.00 price objective for the company. Royal Bank of Canada restated an "outperform" rating and issued a $68.00 price objective on shares of Jasper Therapeutics in a research note on Monday, December 23rd. Finally, HC Wainwright reiterated a "buy" rating and set a $65.00 target price on shares of Jasper Therapeutics in a research note on Thursday, October 24th. Ten investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Jasper Therapeutics has a consensus rating of "Buy" and an average target price of $73.38.

Jasper Therapeutics Stock Up 8.3 %

JSPR stock traded up $1.60 during mid-day trading on Monday, reaching $20.87. 437,201 shares of the stock traded hands, compared to its average volume of 392,765. The firm has a market capitalization of $313.07 million, a PE ratio of -4.40 and a beta of 2.18. The business has a 50-day moving average of $22.05 and a two-hundred day moving average of $20.49. Jasper Therapeutics has a 52 week low of $6.61 and a 52 week high of $31.01.

Hedge Funds Weigh In On Jasper Therapeutics

A number of hedge funds have recently made changes to their positions in JSPR. BNP Paribas Financial Markets raised its holdings in shares of Jasper Therapeutics by 208.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company's stock worth $47,000 after buying an additional 1,698 shares in the last quarter. Wolff Wiese Magana LLC acquired a new position in Jasper Therapeutics during the third quarter worth $59,000. MetLife Investment Management LLC raised its stake in Jasper Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 6,874 shares of the company's stock worth $129,000 after acquiring an additional 3,873 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Jasper Therapeutics during the third quarter valued at $251,000. Finally, Rhumbline Advisers acquired a new stake in shares of Jasper Therapeutics in the 2nd quarter valued at $300,000. Institutional investors and hedge funds own 79.85% of the company's stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.